Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
155 hedge funds and large institutions have $508M invested in Eagle Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 64 increasing their positions, 54 reducing their positions, and 22 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 54
7% less funds holding
Funds holding: 166 → 155 (-11)
11% less capital invested
Capital invested by funds: $574M → $508M (-$65.7M)
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$10.5M |
| 2 |
SGCIA
Smith Graham & Co Investment Advisors
Houston,
Texas
|
+$5.96M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$5.26M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.28M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$15.9M |
| 2 |
AC
Armistice Capital
New York
|
-$7.99M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.75M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$4.8M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$4.04M |
EGRX Hedge Fund Activity: Q1 2021 in Review
155 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2021, worth a combined $508M — down 11% from $574M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of EGRX and 13 opened new positions — a net loss of 9 holders — while 54 trimmed existing stakes and 64 added.
The largest buyer was Brandes Investment Partners, adding an estimated $10.5M. The largest seller was Park West Asset Management, cutting an estimated $15.9M.
- 155 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2021, down from 166 in Q4 2020.
- Funds reported $508M of Eagle Pharmaceuticals, Inc. stock for Q1 2021, down 11% quarter-over-quarter.
- 13 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2021 and 22 closed out, a net change of -9 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2021 was Brandes Investment Partners, an estimated $10.5M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2021 was Park West Asset Management, an estimated $15.9M sold.
Based on aggregated 13F filings for Q1 2021.